Introduction
Inhaled anti-infl ammatory agents and bronchodilators such as corticosteroids, muscarinic antagonists and β 2 -agonists are central to the pharmacological management of chronic obstructive pulmonary disease (COPD) ( 1 , 2 ) . Combinations of drugs with distinct and complementary mechanisms of action may off er improved effi cacy in the treatment of COPD ( 2 ) , which may in turn help to relieve the burden of COPD on daily activities. Furthermore, clinical studies have shown the use of an inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA) combination together with a longacting muscarinic antagonist (LAMA) is well tolerated in patients with COPD and associated with improvements in lung function, symptoms, Published with license by Taylor & Francis and health status compared with individual ICS/LABA or LAMA therapy ( 3 -5 ) . Th ese fi ndings are refl ected in the current version of Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which recommend the combined use of an ICS/LABA product with a LAMA as a secondary treatment option for symptomatic patients with severe airfl ow obstruction and at high risk of exacerbations ( 2 ) .
Fluticasone propionate plus salmeterol (FP/SAL; GSK, London, UK) is an ICS/LABA combination indicated for maintenance treatment of airfl ow obstruction and for reduction of exacerbations in patients with COPD ( 6 ) . Th e LAMA umeclidinium (UMEC, GSK573719; GSK, London, UK) has recently been approved as maintenance treatment for COPD in the US and EU ( 7 , 8 ) . Early dose-ranging studies demonstrated improvements in lung function with UMEC over a dose range of 62.5 to 1000 μg versus placebo (PBO), with no clear dose-diff erentiation ( 9 ) . A further dose-ranging study of UMEC with doses from 15.6 to 125 μg once daily demonstrated dose ordering, with UMEC 125 μg showing the greatest benefi t in lung function and rescue use, yet similar safety profi les to the lower doses ( 10 ) . To fully characterize the effi cacy and safety profi le of UMEC, two doses of UMEC (62.5 and 125 μg) were investigated in subsequent studies.
Here, we report the results of two studies that evaluated the effi cacy and safety of once-daily UMEC (62.5 μg and 125 μg) when added to twice-daily FP/SAL (250/50 μg) in patients with COPD. Th e study was designed primarily to assess lung function, although other endpoints were assessed.
Methods

Study designs
Th e two studies reported here were 12-week, randomized, double-blind, parallel-group studies. Study 1 (ClinicalTrials.gov registration number: NCT01772134; GSK study number: AC4116135) was conducted in Canada, Germany, the Republic of Korea, and the US. Study 2 (ClinicalTrials.gov registration number: NCT01772147; GSK study number: AC4116136) was conducted in Chile, the Czech Republic, the Republic of Korea, Poland, and the United States.
Th e primary objective of both studies was to compare the effi cacy and safety of UMEC (administered at a dose of 62.5 μg or 125 μg) plus FP/SAL (UMEC + FP/SAL) with PBO + FP/SAL in patients with COPD.
Eligible patients were 40 years of age or older and had an established history of COPD as defi ned by the American Th oracic Society/European Respiratory Society ( 11 ) . Inclusion criteria were: current or former cigarette smoker with a smoking history of 10 pack-years or more; a pre-and post-salbutamol (albuterol) forced expiratory volume in 1 second (FEV 1 )-to-forced-vitalcapacity (FVC) ratio < 0.70 and a post-albuterol FEV 1 of 70% of predicted normal values or less (calculated from National Health and Nutrition Examination Survey III reference equations ( 12 , 13 ) ; and a score of 2 or higher on the modifi ed Medical Research Council Dyspnea Scale ( 14 ) at study Visit 1. Exclusion criteria included: hospital admission for COPD or pneumonia within the 12 weeks before study Visit 1; or a present diagnosis of asthma or other known respiratory disorder. Full inclusion and exclusion criteria are described in the Supplementary materials.
Both studies were approved by the relevant local ethics review committees and conducted in accordance with the Declaration of Helsinki ( 15 ) and Good Clinical Practice guidelines. All patients gave written, informed consent before study participation.
Randomization and blinding
Both studies were multicenter, randomized, doubleblind, parallel-group trials. Patients entered a 4-week open-label run-in treatment with FP/SAL 250/50 μg. After the run-in period, the eligible patients were randomly assigned in a 1:1:1 ratio to once-daily UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg), or PBO administered double-blind via ELLIPTA™ dry powder inhaler, plus FP/SAL (250/50 μg administered twice daily, delivering 220/21 μg) administered open-label via DISKUS™ inhaler over a 12-week treatment period. Th e randomization schedule was generated using a validated computerized system (RandAll version 2.14) and patients were randomized using an Interactive Voice Response System. Concurrent use of albuterol was permitted as rescue medication throughout the study.
Outcomes and assessments
For both studies, the primary effi cacy measure was trough FEV 1 at Day 85 (defi ned as the mean of the FEV 1 values obtained 23 and 24 hours after dosing on Day 84). Th e secondary endpoints were weighted-mean (WM) FEV 1 over 0-6 hours post-dose at Day 84 and rescue albuterol use (percentage of rescue-free days and mean number of puff s per day). Th e proportion of patients achieving an increase of ≥ 0.100 L above baseline in trough FEV 1 was also assessed as a lung function endpoint .
It has been reported that a change in pre-dose FEV 1 of approximately 0.100 L can be perceived by patients ( 16 ) , and therefore this was considered a clinicallymeaningful improvement. Other lung function endpoints assessed were: trough FEV 1 George's Respiratory Questionnaire (collected as SGRQ for patients with COPD, but converted to and reported as SGRQ). Baseline measures for the CAT and SGRQ were taken at Visit 2 after 4 weeks of treatment with open-label FP/SAL, consistent with the timing of other baseline assessments. A reduction in SGRQ score of 4 points was considered the minimally clinically important diff erence (MCID) ( 17 ) . Safety and tolerability assessments included the incidence of adverse events (AEs), vital signs (including pulse rate and systolic and diastolic blood pressure), and the recording of COPD exacerbations. Th e incidence of AEs of special interest, including cardiovascular events, was assessed using Standardised Medical Dictionary for Regulatory Activities Queries: cardiac arrhythmias, cardiac failure, ischemic heart disease, central nervous system hemorrhages, cerebrovascular conditions, pneumonia, and lower respiratory tract infections. A COPD exacerbation was defi ned as an acute worsening of symptoms of COPD requiring the use of any treatment beyond study medication or rescue albuterol/salbutamol.
Statistical analyses and sample size considerations
For both studies, sample size calculations used a twosided signifi cance level of 5% and an estimate of the residual standard deviation (SD) for trough FEV 1 of 0.220 L. It was calculated that 160 patients per treatment group would provide 90% power to detect a 0.080 L diff erence between UMEC + FP/SAL treatment groups and PBO + FP/SAL in trough FEV 1 . To account for a 20% withdrawal rate, approximately 600 patients (200 patients per treatment) were to be randomized in each study.
Th e primary analysis was performed on the intentto-treat (ITT) population, which was defi ned as all patients randomized to treatment who received at least one dose of study drug. Th e primary endpoint was analyzed using a mixed models repeated measures (MMRM) analysis ( 18 ) with baseline FEV 1 , smoking status, day (as a categorical variable) and treatment as covariates. Day-by-baseline interaction and day-bytreatment interaction were included to estimate treatment eff ect at each day. Th e model used all available trough FEV 1 values recorded on Days 2, 28, 56, 84, and 85. Th e analysis of 0−6 hours' WM FEV 1 on Day 84 was done in a similar way. Estimated diff erences between each dose of UMEC + FP/SAL and PBO + FP/SAL were presented together with 95% confi dence intervals and p-values. Rescue medication use (mean puff s/day over Weeks 1-12) was analyzed using an analysis of covariance model adjusting for baseline, treatment group, and smoking status.
To account for multiplicity across treatment comparisons and key endpoints, a step-down, closed testing procedure was used (further details are included as Supplementary Materials), as reported previously ( 19 ) .
Results
Patients
In Study 1, 862 patients were enrolled across 16 centers in Canada, 33 centers in Germany, 8 centers in the Republic of Korea, and 13 centers in the US. In total, 617 patients were randomized to treatment, 614 received at least one dose of study medication and were included in the ITT population, and of these 552 (90%) completed the study (Figure 1 A) . In Study 2, 872 patients were enrolled across 8 centers in Chile, 11 centers in the Czech Republic, 8 centers in the Republic of Korea, 8 centers in Poland, and 17 centers in the United States. In total, 608 were randomly assigned to treatment, 606 received at least one dose of study medication and were included in the ITT population, and 532 (88%) completed the study (Figure 1 B) . Patient demographics and characteristics were well balanced between treatment groups and between studies, except the proportion of females in Study 2 was lower for UMEC 62.5 μg + FP/SAL compared with the other treatment groups (Table 1 ) and there were more current smokers in Study 1 (50−57%) than in Study 2 (36−39%). Additional lung function endpoint data for both studies are presented in Table 2 and 
Outcomes
Lung function
Rescue use
In both studies, patients receiving UMEC + FP/SAL (62.5 μg or 125 μg) experienced a greater overall proportion of rescue-free days, and a greater increase from baseline in the proportion of rescue-free days, compared with PBO + FP/SAL (Table 2 ). , withdrew consent ( n = 3), lost to follow-up ( n = 2), protocol deviation ( n = 4), lack of effi cacy ( n = 11), subject reached protocol-stopping criteria ( n = 1); UMEC 62.5 + FP/SAL: PBO + FP/SAL: AE ( n = 5), withdrew consent ( n = 1), protocol deviation ( n = 3), lack of effi cacy ( n = 5); UMEC 125 + FP/SAL: AE ( n = 10), withdrew consent ( n = 5), protocol deviation ( n = 3), lack of effi cacy ( n = 3). Study 2: Reasons for withdrawal: PBO + FP/SAL: AE ( n = 13), withdrew consent ( n = 7), lost to follow-up ( n = 1), protocol deviation ( n = 2), lack of effi cacy ( n = 8); UMEC 62.5 + FP/SAL: AE ( n = 10), withdrew consent ( n = 8), protocol deviation ( n = 1), lack of effi cacy ( n = 6); UMEC 125 + FP/SAL: AE ( n = 6), withdrew consent ( n = 4), lost to follow-up ( n = 1), protocol deviation ( n = 1), lack of effi cacy ( n = 6).
www.copdjournal.com line ( Table 2 ) . In Study 2, the decrease from baseline in both UMEC + FP/SAL groups was close to the MCID for SGRQ (4 units 
Safety and tolerability
In Study 1, the incidence of AEs and serious AEs (SAEs) was similar across treatment groups (Table 3 ) . In Study 2, the overall incidence of on-treatment AEs was similar across the treatment groups, but the incidence of SAEs was higher in the PBO + FP/SAL group (both UMEC + FP/SAL groups: 3%; PBO + FP/SAL: 7%). In Statistically signifi cant reductions in rescue use were observed for both UMEC + FP/SAL groups compared with PBO + FP/SAL in Study 1 (0.3 puff s/day, both p < 0.05; Table 2 ), but only for UMEC 125 μg + FP/SAL in Study 2 (0.5 puff s/day; Table 2 ).
HRQoL
In both studies, numerical decreases in CAT scores (denoting an improvement) were observed in all treatment groups at Day 28 and Day 84 compared with baseline, except for the PBO + FP/SAL group at Day 84 in Study 2 ( Table 2 ) . Decreases in CAT score were > 0.50 greater for all UMEC + FP/SAL groups compared with PBO + FP/SAL on both days, with the exception of Study 1 at Day 84 (Table 2 ) .
Similarly, decreases in SGRQ total score (denoting improvement in HRQoL) were observed for all treatment groups at Day 28 and Day 84 compared with base- www.copdjournal.com both studies, headache and nasopharyngitis were the most commonly reported AEs across all treatment groups (3-7% and 2-5%, respectively; Table 3 ). Additional details on drug-related AEs and AEs of special interest are presented in the Supplementary Materials and Supplementary Table 1 .
In Study 1, one death possibly related to study drug in the UMEC 125 μg + FP/SAL group was reported in a patient with extensive cardiovascular disease (additional details provided in Supplementary Materials). In Study 2, two deaths were reported during the treatment phase; one in the PBO + FP/SAL group and one in the UMEC 62.5 μg + FP/SAL group (additional details provided in Supplementary Materials). Neither of the deaths were considered to be related to the study drug.
No clinically relevant treatment-related changes in vital signs were reported in either study. In both studies, fewer on-treatment COPD exacerbations were reported with either dose of UMEC + FP/SAL compared with PBO + FP/SAL (Table 3 ) .
Discussion
Th e fi ndings from these two randomized, double-blind, parallel-group studies show that the addition of oncedaily UMEC (62.5 or 125 μg) to twice-daily FP/SAL (250/50 μg) resulted in statistically signifi cant and clinically-meaningful improvements in measures of lung function when compared with PBO + FP/SAL over 12 weeks in patients with COPD. A statistically signifi cant reduction in rescue medication use, an objective measure of improvement noticeable by patients, was also observed with UMEC 125 μg + FP/SAL compared with PBO + FP/SAL in both studies, and with UMEC 62.5 μg + FP/SAL in Study 1. Th ese fi ndings are consistent with the results of other clinical studies of UMEC 62.5 and 125 μg, which reported improvements in trough FEV 1 , dyspnea (as measured by transitional dsypnea index), HRQoL (as measured by the SGRQ) and rescue medication use (i.e., a reduction) compared with PBO ( 10 , 20 , 21 ) . Th is indicates that the benefi t of UMEC monotherapy over PBO is maintained when administered on a background of ICS/LABA therapy.
Th e combined use of ICS and/or LABA or LAMA therapy is recommended as a fi rst-line therapy for patients with symptomatic COPD and a high risk of exacerbations ( 2 ) . Th e addition of a LAMA to ICS/LABA therapy may also provide increased effi cacy compared with ICS/LABA therapy alone. Th is is supported by clinical study data showing that the addition of tiotropium (LAMA) to ICS/LABA therapy (budesonide/formoterol or FP/SAL) resulted in improvements in lung function, COPD symptoms, health status and severe exacerbations (i.e., a reduction) versus tiotropium alone ( 4 , 5 , 22 -24 ) . Th ese studies also showed that the number and type of AEs reported with triple therapy were generally similar to those reported with dual or monotherapy agents for periods of up to one year, and were mostly related to their pharmacological mode of action.
A recent retrospective study conducted in a UKbased COPD cohort (National Health Service Tayside Respiratory Disease Information System) also assessed the impact of adding tiotropium to ICS/LABA therapy ( 25 ) . Th is study revealed that triple therapy may reduce all-cause mortality, hospital admissions and oral corticosteroid bursts compared with ICS/LABA therapy alone. Overall, the results of this study support the rationale for LAMA/ICS/LABA triple therapy in COPD and extend the results of similar studies ( 3 , 4 , 26 ) , with UMEC + FP/SAL providing more eff ective bronchodilation at the beginning and end of the dosing interval compared with PBO + FP/SAL.
All three treatments (PBO + FP/SAL, UMEC 125 μg + FP/SAL, and UMEC 62.5 μg + FP/SAL) demonstrated improvements from baseline in CAT scores. Recently, an MCID of 2 points was identifi ed by Kon et al. ( 27 ) . Although the diff erences from baseline reported in this study did not reach that magnitude (improvements of 0.81-1.42 for active treatments), it should be considered that the MCID was identifi ed for a change from (untreated) baseline, whereas in these studies the baseline measurement was taken after a 4-week period on active treatment for COPD (FP/SAL). Th ese additional improvements over FP/SAL therapy therefore represent a potentially clinically meaningful diff erence to PBO alone. Improvements from baseline were also noted in SGRQ scores with the three treatment groups.
However, no consistent statistically signifi cant diff erences in SGRQ total score were observed between the treatment groups, with the exception of UMEC 125 μg + FP/SAL compared with PBO + FP/SAL in Study 2. It is unclear why diff erences were not observed between the UMEC + FP/SAL and PBO + FP/SAL treatment groups across these two studies, as improvements in rescue use were observed. One potential reason may be that baseline SGRQ and CAT scores were measured after 4 weeks of treatment with FP/SAL. In addition, the two studies were designed to evaluate lung function effi cacy www.copdjournal.com measures, and larger studies may be required to determine a benefi t on patient-reported outcomes.
Both doses of UMEC + FP/SAL were well tolerated, with the overall incidence of on-treatment AEs similar to PBO + FP/SAL in both studies. In the two studies reported here, the combination of UMEC (a LAMA) with FP/SAL (an ICS/LABA) did not result in increased cardiovascular AEs. Overall, both doses of UMEC + FP/SAL demonstrated similar effi cacy and safety in the overall study population, and no substantial clinical benefi t was observed with the UMEC 125-μg dose over the UMEC 62.5-μg dose when added to FP/SAL.
Although these studies demonstrate that the addition of UMEC to FP/SAL results in clinically signifi cant improvements in lung function, they were not designed to assess the eff ect of the addition of UMEC to FP/SAL on exacerbations, which may require studies of longer duration and larger sample size. Th ese studies would also provide longer-term safety data on the triple regimen. As such, the role of triple LAMA/LABA/ICS therapy compared with dual LAMA/LABA therapy in the COPD treatment paradigm is still under investigation.
Conclusions
Th e fi ndings from both studies demonstrate that the addition of UMEC 62.5 μg or UMEC 125 μg to FP/SAL resulted in statistically signifi cant improvements in measures of lung function compared with PBO + FP/ SAL over 12 weeks. Both doses of UMEC + FP/SAL were well tolerated, with no notable treatment-related diff erences in AEs or changes in vital signs, and no additional safety concerns identifi ed with the addition of UMEC to FP/SAL over a 12-week treatment period. Overall, these data suggest that patients with COPD can obtain additional benefi ts from the addition of UMEC to FP/SAL.
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